U.S. markets open in 9 hours 10 minutes

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.87+0.12 (+1.37%)
At close: 04:00PM EDT
8.87 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close8.75
Bid5.20 x 800
Ask18.19 x 900
Day's Range8.56 - 8.91
52 Week Range6.30 - 17.53
Avg. Volume246,761
Market Cap544.265M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.05
Earnings DateAug 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
70% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BVS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bioventus Inc.
    Analyst Report: Zimmer Biomet Holdings, Inc.Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • GlobeNewswire

    Bioventus Receives FDA 510(k) Clearance for SonaStar Elite

    Innovative New Handpiece Addition to the Nexus Ultrasonic Generator Significantly Expands Company’s Offering in Neurosurgery Ablation Procedures DURHAM, N.C., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s neXus® SonaStar Elite® handpiece. The SonaStar Elite (SSE) handpiece is powered by the neXus Ult

  • GlobeNewswire

    Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022

    DURHAM, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market opens on Thursday, August 11, 2022. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dia

  • GlobeNewswire

    Bioventus Completes CartiHeal Acquisition

    DURHAM, N.C., July 12, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has completed its acquisition of CartiHeal. “We are excited to add CartiHeal to our diverse portfolio of active healing solutions,” commented Ken Reali, Bioventus’ chief executive officer. “CartiHeal represents an important breakthrough for the treatment of osteoarthritis and osteochondral defects of the knee with